Celularity Inc.
NASDAQ:CELU
1.55 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Celularity Inc. |
Symbool | CELU |
Munteenheid | USD |
Prijs | 1.55 |
Beurswaarde | 34,076,130 |
Dividendpercentage | 0% |
52-weken bereik | 1.3 - 7.97 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Robert Joseph Hariri M.D., Ph.D. |
Website | https://www.celularity.com |
An error occurred while fetching data.
Over Celularity Inc.
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)